INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.

The INSM1 gene encodes a developmentally regulated zinc finger transcription factor. INSM1 expression is normally absent in adult tissues, but is reactivated in neuroendocrine tumor cells. In the present study, we analyzed the therapeutic potential of an adenoviral INSM1 promoter-driven herpes simplex virus thymidine kinase (HSV-tk) construct in primitive neuroectodermal tumors (PNETs). We constructed an adenoviral INSM1 promoter-driven HSV-tk gene for therapy in PNETs. The PNET-specific adeno-INSM1 promoter HSV-tk construct was tested both in vitro and in vivo in a nude mouse tumor model. Northern blot analysis and transient transfection of an INSM1 promoter-driven luciferase reporter gene indicated that the INSM1 promoter was active in neuroblastoma (IMR-32), retinoblastoma (Y79), and medulloblastoma (D283 Med) cells, but not in glioblastoma (U-87 MG) cells. After Ad-INSM1p-HSV-tk infection, the levels of HSV-tk protein expression were consistent with INSM1 promoter activities. Furthermore, in vitro multiplicity of infection and ganciclovir (GCV) sensitivity studies indicated that the INSM1 promoter could mediate specific expression of the HSV-tk gene and selective killing of INSM1-positive PNETs. In vivo intratumoral adenoviral delivery demonstrated that the INSM1 promoter could direct HSV-tk gene expression in a nude mouse tumor model and effectively repressed tumor growth in response to GCV treatment. Taken together, our data show that the INSM1 promoter is specific and effective for targeted cancer gene therapy in PNETs.

[1]  S. Pääbo,et al.  Insulinoma-Associated 1 Has a Panneurogenic Role and Promotes the Generation and Expansion of Basal Progenitors in the Developing Mouse Neocortex , 2008, Neuron.

[2]  M. Breslin,et al.  Identification of an INSM1-binding site in the insulin promoter: negative regulation of the insulin gene transcription. , 2008, The Journal of endocrinology.

[3]  C. Birchmeier,et al.  Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympatho-adrenal lineage , 2008, Development.

[4]  M. Breslin,et al.  Neurogenin 3 recruits CBP co‐activator to facilitate histone H3/H4 acetylation in the target gene INSM1 , 2007, FEBS letters.

[5]  C. Birchmeier,et al.  The zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells. , 2006, Genes & development.

[6]  M. Breslin,et al.  The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer , 2006, Cancer Gene Therapy.

[7]  R. F. Luco,et al.  IA1 is NGN3‐dependent and essential for differentiation of the endocrine pancreas , 2006, The EMBO journal.

[8]  D. Frappaz,et al.  Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Seth.  Vector-mediated cancer gene therapy: An overview , 2005, Cancer biology & therapy.

[10]  H. Uramoto,et al.  Neuroblastoma‐specific cytotoxicity mediated by the Mash1‐promoter and E. coli purine nucleoside phosphorylase , 2005, Pediatric blood & cancer.

[11]  N. Rainov,et al.  A Neuroblastoma-Selective Suicide Gene Therapy Approach Using the Tyrosine Hydroxylase Promoter , 2004, Pediatric Research.

[12]  M. Breslin,et al.  NeuroD1/E47 Regulates the E-box Element of a Novel Zinc Finger Transcription Factor, IA-1, in Developing Nervous System* , 2003, Journal of Biological Chemistry.

[13]  M. Black,et al.  Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing , 2003, Cancer Gene Therapy.

[14]  N. Pedersen,et al.  Transcriptional gene expression profiling of small cell lung cancer cells. , 2003, Cancer research.

[15]  M. Lan,et al.  The zinc-finger transcription factor INSM1 is expressed during embryo development and interacts with the Cbl-associated protein. , 2002, Genomics.

[16]  D. Curiel,et al.  Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor. , 2002, Journal of pediatric surgery.

[17]  M. Breslin,et al.  Expression of a Novel Zinc-Finger cDNA, IA-1, Is Associated with Rat AR42J Cells Differentiation into Insulin-Positive Cells , 2002, Pancreas.

[18]  M. Breslin,et al.  Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: identification of consensus IA-1 binding sequence. , 2002, Nucleic acids research.

[19]  M. Iyer,et al.  Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Hatano,et al.  Tissue-specific expression of a suicide gene for selective killing of neuroblastoma cells using a promoter region of the NCX gene , 2001, Cancer Gene Therapy.

[21]  M. Black,et al.  Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. , 2001, Cancer research.

[22]  F. Berthold,et al.  Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. , 2000, Drugs.

[23]  L. Rorke,et al.  Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Weitzman,et al.  Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer , 1999, Gene Therapy.

[25]  Y. Vergouwe,et al.  Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration , 1998, Gene Therapy.

[26]  K. Willecke,et al.  Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  X. -. Chen,et al.  Combination gene therapy for liver metastasis of colon carcinoma in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Woo,et al.  Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. , 1995, Cancer research.

[29]  M. de Silva,et al.  A novel human insulinoma-associated cDNA, IA-1, encodes a protein with "zinc-finger" DNA-binding motifs. , 1992, The Journal of biological chemistry.

[30]  Giuseppe Giannini,et al.  An integrated approach identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated genes in developing cerebellum and medulloblastoma. , 2008, Neoplasia.

[31]  B. Dörken,et al.  Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. , 1997, Cancer gene therapy.

[32]  R. Evans,et al.  Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. , 1990, Human gene therapy.